These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 15448106

  • 1. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy.
    Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, Abuelo D, Phornphutkul C, Molnes J, Bell GI, Gloyn AL, Hattersley AT, Molven A, Søvik O, Njølstad PR.
    Diabetes; 2004 Oct; 53(10):2713-8. PubMed ID: 15448106
    [Abstract] [Full Text] [Related]

  • 2. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
    Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ.
    Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
    [Abstract] [Full Text] [Related]

  • 3. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.
    Proks P, Girard C, Baevre H, Njølstad PR, Ashcroft FM.
    Diabetes; 2006 Jun; 55(6):1731-7. PubMed ID: 16731836
    [Abstract] [Full Text] [Related]

  • 4. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.
    Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njølstad PR, Ashcroft FM, Hattersley AT.
    N Engl J Med; 2004 Apr 29; 350(18):1838-49. PubMed ID: 15115830
    [Abstract] [Full Text] [Related]

  • 5. Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.
    Kim MS, Kim SY, Kim GH, Yoo HW, Lee DW, Lee DY.
    J Korean Med Sci; 2007 Aug 29; 22(4):616-20. PubMed ID: 17728498
    [Abstract] [Full Text] [Related]

  • 6. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
    Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT, Neonatal Diabetes International Collaborative Group.
    N Engl J Med; 2006 Aug 03; 355(5):467-77. PubMed ID: 16885550
    [Abstract] [Full Text] [Related]

  • 7. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
    Babiker T, Vedovato N, Patel K, Thomas N, Finn R, Männikkö R, Chakera AJ, Flanagan SE, Shepherd MH, Ellard S, Ashcroft FM, Hattersley AT.
    Diabetologia; 2016 Jun 03; 59(6):1162-6. PubMed ID: 27033559
    [Abstract] [Full Text] [Related]

  • 8. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients.
    Vaxillaire M, Populaire C, Busiah K, Cavé H, Gloyn AL, Hattersley AT, Czernichow P, Froguel P, Polak M.
    Diabetes; 2004 Oct 03; 53(10):2719-22. PubMed ID: 15448107
    [Abstract] [Full Text] [Related]

  • 9. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.
    Flechtner I, de Lonlay P, Polak M.
    Diabetes Metab; 2006 Dec 03; 32(6):569-80. PubMed ID: 17296510
    [Abstract] [Full Text] [Related]

  • 10. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
    Tonini G, Bizzarri C, Bonfanti R, Vanelli M, Cerutti F, Faleschini E, Meschi F, Prisco F, Ciacco E, Cappa M, Torelli C, Cauvin V, Tumini S, Iafusco D, Barbetti F, Early-Onset Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetology.
    Diabetologia; 2006 Sep 03; 49(9):2210-3. PubMed ID: 16816952
    [No Abstract] [Full Text] [Related]

  • 11. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.
    Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT, Neonatal Diabetes International Collaborative Group.
    Diabetes Care; 2008 Feb 03; 31(2):204-9. PubMed ID: 18025408
    [Abstract] [Full Text] [Related]

  • 12. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation.
    Klupa T, Edghill EL, Nazim J, Sieradzki J, Ellard S, Hattersley AT, Malecki MT.
    Diabetologia; 2005 May 03; 48(5):1029-31. PubMed ID: 15838686
    [No Abstract] [Full Text] [Related]

  • 13. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
    Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, Gnasso A, Grupillo M, Lauro R, Hribal ML, Perticone F, Marchetti P.
    J Clin Endocrinol Metab; 2006 Jun 03; 91(6):2334-9. PubMed ID: 16595597
    [Abstract] [Full Text] [Related]

  • 14. Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes.
    Girard CA, Wunderlich FT, Shimomura K, Collins S, Kaizik S, Proks P, Abdulkader F, Clark A, Ball V, Zubcevic L, Bentley L, Clark R, Church C, Hugill A, Galvanovskis J, Cox R, Rorsman P, Brüning JC, Ashcroft FM.
    J Clin Invest; 2009 Jan 03; 119(1):80-90. PubMed ID: 19065048
    [Abstract] [Full Text] [Related]

  • 15. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
    Lau E, Correia C, Freitas P, Nogueira C, Costa M, Saavedra A, Costa C, Carvalho D, Fontoura M.
    Arch Endocrinol Metab; 2015 Dec 03; 59(6):559-61. PubMed ID: 26331221
    [Abstract] [Full Text] [Related]

  • 16. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype.
    Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT.
    Diabetologia; 2006 Jun 03; 49(6):1190-7. PubMed ID: 16609879
    [Abstract] [Full Text] [Related]

  • 17. Neonatal diabetes caused by a homozygous KCNJ11 mutation demonstrates that tiny changes in ATP sensitivity markedly affect diabetes risk.
    Vedovato N, Cliff E, Proks P, Poovazhagi V, Flanagan SE, Ellard S, Hattersley AT, Ashcroft FM.
    Diabetologia; 2016 Jul 03; 59(7):1430-1436. PubMed ID: 27118464
    [Abstract] [Full Text] [Related]

  • 18. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
    Al-Mahdi M, Al Mutair A, Al Balwi M, Hussain K.
    Ann Saudi Med; 2010 Jul 03; 30(2):162-4. PubMed ID: 20220270
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P, Sulen Å, Barbetti F, Beltrand J, Svalastoga P, Codner E, Tessmann EH, Juliusson PB, Skrivarhaug T, Pearson ER, Flanagan SE, Babiker T, Thomas NJ, Shepherd MH, Ellard S, Klimes I, Szopa M, Polak M, Iafusco D, Hattersley AT, Njølstad PR, Neonatal Diabetes International Collaborative Group.
    Lancet Diabetes Endocrinol; 2018 Aug 03; 6(8):637-646. PubMed ID: 29880308
    [Abstract] [Full Text] [Related]

  • 20. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.
    Zung A, Glaser B, Nimri R, Zadik Z.
    J Clin Endocrinol Metab; 2004 Nov 03; 89(11):5504-7. PubMed ID: 15531505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.